LONDON, June 3 (Reuters) - An HIV drug first approved less than three years is to be rolled out in Botswana as a first-line core medicine to treat newly diagnosed patients under a contract agreed between the government and ViiV Healthcare.
ViiV, which is majority-owned by GlaxoSmithKline, said on Friday it was the first time Tivicay, or dolutegravir, was being made available as part of a national health programme in sub-Saharan Africa. No financial details were given.
Pfizer and Shionogi also hold minority stakes in ViiV.
(Reporting by Ben Hirschler; editing by Jason Neely)